Innovent Biologics, Inc. (OTCMKTS:IVBXF) Short Interest Up 88.4% in February

Innovent Biologics, Inc. (OTCMKTS:IVBXF) was the recipient of a large growth in short interest during the month of February. As of February 13th, there was short interest totaling 526,150 shares, a growth of 88.4% from the January 29th total of 279,298 shares. Based on an average daily volume of 4,888 shares, the short-interest ratio is currently 107.6 days. Based on an average daily volume of 4,888 shares, the short-interest ratio is currently 107.6 days.

Innovent Biologics Trading Up 3.7%

Shares of IVBXF opened at $11.30 on Monday. The business’s fifty day moving average price is $10.77 and its two-hundred day moving average price is $11.50. Innovent Biologics has a 52 week low of $4.69 and a 52 week high of $15.12.

Innovent Biologics Company Profile

Innovent Biologics is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of high-quality biologic therapies. Founded in 2011 and headquartered in the Suzhou National Biotech R&D Park, the company specializes in innovative treatments across oncology, metabolic and ophthalmology indications. Innovent’s integrated model encompasses end-to-end capabilities, from early discovery and clinical development to large-scale manufacturing and market launch.

The company has built a diversified product portfolio that includes the anti-PD-1 monoclonal antibody sintilimab (Tyvyt), approved for lymphoma and non-small cell lung cancer in China, as well as multiple biosimilars such as IBI305 (a bevacizumab biosimilar) and IBI306 (an etanercept biosimilar).